Perényi A, Goswami U, Frecska E, Majláth E, Barcs G, Kassay-Farkas A
National Institute for Nervous and Mental Diseases, Budapest, Hungary.
Pharmacopsychiatry. 1989 May;22(3):108-10. doi: 10.1055/s-2007-1014590.
The authors administered haloperidol 4.5 mg t.i.d. to 33 drug-free schizophrenic patients. Ten patients did not receive anything else (group HPL), while ten patients received procyclidine 5 mg t.i.d., and 13 patients were given promethazine 25 mg t.i.d. (groups HPRC and HPRM respectively) in addition. Seven patients dropped out of the HPL group and three out of the HPRM group, but none out of the HPRC group. These drop outs were due to the development of early extrapyramidal side effects, which were absent in the HPRC group. The findings suggest that antiparkinson prophylaxis is useful during commencement of therapy with high-potency neuroleptic agents.
作者对33名未服用过药物的精神分裂症患者每日三次给予4.5毫克氟哌啶醇。10名患者未接受其他任何药物（HPL组），10名患者每日三次接受5毫克丙环定，另外13名患者每日三次接受25毫克异丙嗪（分别为HPRC组和HPRM组）。HPL组有7名患者退出，HPRM组有3名患者退出，但HPRC组无人退出。这些退出是由于早期锥体外系副作用的出现，而HPRC组未出现此类副作用。研究结果表明，在开始使用高效抗精神病药物治疗期间，预防帕金森病是有用的。
